Hepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review
Liu, Jing; Sun, Bingbing; Yin, Huijun; Liu, Sijin
刊名MEDICINE
2016-04
卷号95期号:14页码:-
英文摘要Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and beta-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and beta-thalassemia), hepatic hepcidin concentration is significantly reduced. Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin. Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated. Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve beta-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.
收录类别SCI
内容类型期刊论文
源URL[http://ir.rcees.ac.cn/handle/311016/35864]  
专题生态环境研究中心_环境化学与生态毒理学国家重点实验室
推荐引用方式
GB/T 7714
Liu, Jing,Sun, Bingbing,Yin, Huijun,et al. Hepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review[J]. MEDICINE,2016,95(14):-.
APA Liu, Jing,Sun, Bingbing,Yin, Huijun,&Liu, Sijin.(2016).Hepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review.MEDICINE,95(14),-.
MLA Liu, Jing,et al."Hepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review".MEDICINE 95.14(2016):-.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace